Article Figures & Data
Figures
- Figure 1.
Relative risk reductions in stroke or systemic embolism and major hemorrhage by novel oral anticoagulants versus warfarin in patients with moderate CKD. Patients with CKD had estimated creatinine clearances of 30–49 ml/min, except for those treated with apixaban (25–50 ml/min). Risk reductions were statistically significant for dabigatran (150 mg) on stroke and apixaban on major hemorrhage. Reprinted from reference 6, with permission.
- Figure 2.
Hazard ratios (HRs) for subgroups of patients with CKD stage 3 from two randomized trials comparing anticoagulation with aspirin. For warfarin comparison from the SPAF III Study, the outcome was ischemic stroke and systemic embolism, and the aspirin group additionally received low ineffective doses of warfarin. For apixaban, the outcome was stroke and systemic embolism. 95% CI, 95% confidence interval; INR, international normalized ratio SPAF III, Stroke Prevention in Atrial Fibrillation. Reprinted from reference 6, with permission.
In this issue
